The Types segment classifies solutions by underlying technology: NGS‑based panels, Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Targeted PCR/Array, and Bioinformatics platforms. NGS‑based panels focus on curated gene sets linked to specific disease phenotypes, offering cost‑effective, high‑sensitivity testing that fuels adoption in both clinical and screening contexts. WES expands coverage to all coding regions, supporting broader diagnostic yield for atypical presentations and thus attracting tertiary care centers. WGS provides the most comprehensive genomic view, increasingly justified by declining sequencing costs and its utility in uncovering structural variants, contributing a growing share of high‑value contracts. Targeted PCR/Array methods remain relevant for rapid, low‑complexity assays targeting known pathogenic variants, especially in resource‑limited settings. Finally, Bioinformatics platforms underpin data interpretation, variant annotation, and reporting, acting as a critical enabler across all technology types. Together, these types define the market taxonomy and determine the allocation of investment, pricing structures, and overall market expansion.